The College of Doctors and Surgeon of Ontario (CDSO) has voted in favour of allowing physicians to use heart rate variability (HRV) equipment.
The recommendation was approved by the Board of Directors in a vote last week.
In 2016, the College voted in support of a motion that was then passed by the board and adopted by the Medical Society of Ontario.
It is not yet clear what the impact of this recommendation will be.
The College also approved the recommendation for physicians to conduct studies in which patients with heart disease or stroke are randomized to receive either a cardiac ultrasound device or a standard cardiac monitor.
The devices are available through the CDSO and they will be used to assess whether the device can improve the patients’ cardiac function.
The study will be conducted over a two-year period.
CDSOs are medical societies with more than 100,000 members.
The college does not have the resources to conduct research, and there is currently no clinical trial for HRV.
However, there is evidence that HRV can be beneficial in improving the heart and circulatory system.
In 2015, a study conducted by a group of researchers at McGill University, University of Toronto, and the University of Ottawa reported that HRVs improved the quality of cardiac function in patients with pre-existing heart disease.
Other research has indicated that HRVR devices have been used in patients who had already had a heart attack.
“The CDSCO has taken a strong stand in support for cardiac health and wellness,” said Dr. James McQuarrie, the C&SO president.
“This is a major milestone for us in advancing this research, with the goal of identifying if HRV could be a potential therapeutic intervention in the future.”
A key reason why the CDPO has endorsed HRV is because of the potential for it to be used as a tool for prevention of heart disease and stroke.
The National Institute for Health Research has recommended that HRVT be used in combination with cardiac monitoring in the prevention of sudden cardiac death and other complications associated with cardiac disease.
In a 2016 review of the available evidence on HRV, the Cochrane Collaboration concluded that HRVD has been associated with an improved prognosis for patients with a first or second episode of coronary artery disease.
The CDPOs board noted that HRVA is not only effective in detecting and preventing coronary heart disease, but also with the possibility of improving the patient’s quality of life.
“There are a number of indications in the literature for HRVA, such as prevention of hypertension and the reduction of angina,” said CDPOO Chair of the Board Dr. Karen Haskins.
“HRVA also offers the potential to provide better outcomes in patients presenting with cardiac symptoms, such that patients with coronary artery diseases could be protected from complications.”
HRV also has potential for enhancing cardiac function and reducing the risk of heart attacks and strokes, but there is no evidence it is an effective treatment for all patients.
The Canadian Heart Foundation estimates that HRVC has been found to reduce the risk by 80 per cent and reduce the duration of hospitalization by 20 per cent for patients who are overweight and obese.
The CFHI has also said that HRVE is a “prophylactic” in the event of a cardiac arrest and is not recommended in patients on dialysis, in patients taking a beta blocker drug, or in patients in cardiac rehabilitation.
The committee noted that many patients are reluctant to use HRV due to the risks associated with using it.
“Given that this is a recommendation that is based on a limited number of studies, it is not known whether HRV will prove to be as effective in all patients, or whether HRVE will actually be harmful,” said the CFHI.
“However, the CFHEF has stated that patients who use HRVT in the absence of heart failure should not use it in patients that are on dialysysis.
There are no data on the use of HRVT among patients who have heart failure or in the general population, nor are there data on whether HRVT will be beneficial or harmful for patients in the latter two cases.”
The CFHEP recommends that patients undergoing elective surgery should not be switched to HRV and is recommending that the CFPH continue to recommend HRV as a treatment option for all patient groups.
A study by the Canadian Heart Association found that HRVS were less likely to cause severe bleeding or other cardiac events than standard cardiac monitors.
“Our research shows that patients do not need to worry about HRV or monitor devices,” said Prof. Michael Lohman, the director of the CFHU.
“They should use a standard heart rate monitor.
However the CFHA’s recommendation, based on limited evidence, that patients should not switch to HRVS is premature.
It needs to be reviewed and further studies need to be done to